Omniscient Neurotechnology (o8t®), a Sydney, Australia-based pioneer of AI-driven brain analysis technology, raised US$27.2 million in Series D funding.
OIF Ventures and the Australian National Reconstruction Fund Corporation (NRFC) co-led the investment round with participation from long-term investors including Will Vicars and Gina Rinehart AO.
With the fresh funding, Omniscient plans to accelerate the US commercial expansion of its Quicktome platform and develop new clinical applications, extending its reach into high-growth areas such as brain-computer interfaces, stroke care, and movement disorders.
“AI lets us turn the vast complexity of the human brain into clear, actionable intelligence,” said Stephen Scheeler, CEO of Omniscient. “This funding scales that capability, bringing AI-driven precision brain medicine to patients, physicians, and partners in the US and worldwide.”
Digital health companies, including neurotech startups, have secured more than $180 billion in funding to date, according to our recent Funding Database.
More recently, Sychedelic, a neurotechnology startup developing closed-loop wearable neuromodulation systems designed to help individuals relax, sleep, and focus better, raised $3.5 million in seed funding to launch its wearable neuromodulation headphones.
In another deal, Click Therapeutics, a developer of AI-based digital therapeutics, raised $50 million in Series D funding from Boehringer Ingelheim to support the commercialization of its CT-155, an investigational prescription digital therapeutic that is being studied for the treatment of the experiential negative symptoms of schizophrenia in adults aged 18 years and older.